[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659162":3},{"organization":4,"outcomesModule":7,"designInfo":40,"detailedDescription":53,"studyPopulation":39,"armGroups":54,"interventions":67,"overallOfficials":39,"centralContacts":39,"locations":87,"responsibleParty":108,"collaborators":110,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":115,"sex":121,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":39,"studyType":127,"phases":128,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":90,"whyStopped":39,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Vidya USA Corporation","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":26,"otherOutcomes":39},[9,13,17,20,23],{"measure":10,"description":11,"timeFrame":12},"Change in Menopausal Rating Scale total score","Change from baseline to Week 12 in menopausal symptom severity measured using the Menopausal Rating Scale (MRS). The MRS consists of 11 items assessing menopausal symptoms. The total score ranges from 0 to 44, with higher scores indicating greater symptom severity. A decrease in MRS total score indicates improvement in menopausal symptom burden.","Baseline (Day 0) to Week 12 (Day 84)",{"measure":14,"description":15,"timeFrame":16},"Change in Greene Climacteric Scale total score","Change from baseline to Week 12 in menopausal symptom severity measured using the Greene Climacteric Scale (GCS). The total score will be calculated according to the validated scoring method for the instrument. Higher scores indicate greater menopausal symptom severity. A decrease in GCS total score indicates improvement in menopausal symptom burden.","Baseline (Day 0) to Week 12 (Day",{"measure":18,"description":19,"timeFrame":12},"Change in Kupperman Menopausal Index total score","Change from baseline to Week 12 in menopausal symptom severity measured using the Kupperman Menopausal Index (KMI). The total score is calculated according to the validated KMI scoring method. Higher scores indicate greater menopausal symptom severity. A decrease in KMI total score indicates improvement in menopausal symptom burden.",{"measure":21,"description":22,"timeFrame":12},"Change in serum follicle-stimulating hormone concentration","Change from baseline to Week 12 in serum follicle-stimulating hormone (FSH) concentration. Serum FSH will be measured from blood samples collected at baseline and Week 12. The outcome will be reported as the change in FSH concentration from baseline to Week 12.\n\nUnit of Measure - mIU\u002FmL",{"measure":24,"description":25,"timeFrame":12},"Change in serum estradiol concentration","Change from baseline to Week 12 in serum estradiol concentration. Serum estradiol will be measured from blood samples collected at baseline and Week 12. The outcome will be reported as the change in estradiol concentration from baseline to Week 12.\n\nUnit of Measure - pg\u002FmL",[27,30,33,36],{"measure":28,"description":29,"timeFrame":12},"Change in Menopause-Specific Quality of Life Questionnaire score","Change from baseline to Week 12 in menopause-related quality of life measured using the Menopause-Specific Quality of Life Questionnaire (MENQOL). The score will be calculated according to the validated scoring method for the instrument. Higher scores indicate greater symptom impact and poorer menopause-related quality of life.",{"measure":31,"description":32,"timeFrame":12},"Change in Patient-Reported Outcomes Measurement Information System Anxiety Short Form 4a score","Change from baseline to Week 12 in anxiety symptoms measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 4a. The score will be reported using the instrument's standardized scoring method. Higher scores indicate greater anxiety severity.",{"measure":34,"description":35,"timeFrame":12},"Change in Patient-Reported Outcomes Measurement Information System Cognitive Function Abilities Short Form 4a score","Change from baseline to Week 12 in perceived cognitive function measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function Abilities Short Form 4a. The score will be reported using the instrument's standardized scoring method. Higher scores indicate better perceived cognitive function.",{"measure":37,"description":38,"timeFrame":12},"Change in Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 4a score","Change from baseline to Week 12 in sleep disturbance measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form 4a. The score will be reported using the instrument's standardized scoring method. Higher scores indicate greater sleep disturbance.",null,{"allocation":41,"interventionModel":42,"interventionModelDescription":43,"primaryPurpose":44,"observationalModel":39,"timePerspective":39,"maskingInfo":45},"RANDOMIZED","PARALLEL","This is a randomized, double-blind, placebo-controlled, parallel-group study. Eligible participants will be randomly assigned in a 1:1 ratio to receive either the active intervention containing Ashoka Bark and Shatavari or a matched placebo. Participants will remain in their assigned treatment group throughout the 12-week study period. Study participants, investigators, and personnel involved in outcome assessments and data analysis will remain blinded to treatment assignment until completion of the study and database lock. Outcomes will be compared between the active intervention and placebo groups to evaluate the effect of the botanical supplement on menopausal symptoms, hormonal measures, quality of life, and exploratory microbiome outcomes.","TREATMENT",{"masking":46,"maskingDescription":47,"whoMasked":48},"QUADRUPLE","Participants, investigators, care providers, and outcomes assessors will be blinded to treatment assignment. The active intervention and placebo will be matched in appearance and administered under blinded conditions. Randomization codes will be securely maintained and will remain inaccessible to study personnel involved in participant management, outcome assessment, and data analysis until completion of the study and final database lock, except in cases where emergency unblinding is required for participant safety.",[49,50,51,52],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","Menopause is a natural biological transition resulting from the progressive decline of ovarian function and decreased production of estrogen and progesterone. This hormonal transition is commonly accompanied by elevations in follicle-stimulating hormone (FSH) and a wide range of symptoms, including vasomotor symptoms (hot flashes and night sweats), sleep disturbances, mood changes, cognitive complaints, fatigue, urogenital symptoms, and reductions in overall quality of life. Approximately 1.3 million women enter menopause annually in the United States, and nearly 75% experience symptoms that are moderate to severe. The resulting impact on healthcare utilization, work productivity, and quality of life contributes substantially to the national healthcare burden.\n\nHormonal changes associated with menopause also influence the composition of the vaginal and skin microbiomes. Declining estrogen levels are associated with reductions in Lactobacillus species, altered microbial diversity, decreased epithelial integrity, reduced skin hydration, and increased susceptibility to irritation and infection. Although these biological changes have been increasingly recognized, relatively few interventional studies have evaluated whether botanical therapies influence both menopausal symptoms and the vaginal microbial environment.\n\nHormone replacement therapy (HRT) remains an effective treatment for many women but is not appropriate or acceptable for all individuals because of contraindications, safety concerns, or personal preference. Consequently, there is growing interest in safe, evidence-based, non-hormonal interventions that may alleviate menopausal symptoms while minimizing treatment-related risks.\n\nAshoka Bark (Saraca asoca) and Shatavari (Asparagus racemosus) have been used for centuries in traditional systems of medicine to support women's reproductive and hormonal health. Both botanicals contain naturally occurring bioactive compounds with reported phytoestrogenic, antioxidant, anti-inflammatory, and adaptogenic properties that may contribute to improvements in menopausal symptoms. Preliminary evidence suggests these ingredients may support hormonal balance, emotional well-being, sleep quality, and overall quality of life; however, high-quality randomized, placebo-controlled clinical trials remain limited. Additional well-designed clinical research is needed to evaluate their efficacy and safety using standardized outcome measures and objective biological assessments.\n\nThe present study has been designed to evaluate a proprietary botanical formulation containing Ashoka Bark and Shatavari (\"Beauty Within\") in women experiencing menopausal symptoms. The study seeks to determine whether daily supplementation produces clinically meaningful improvements in menopausal symptom severity, hormone profiles, and health-related quality of life compared with placebo in the post-menopausal women. This randomized, placebo-controlled, 12-week clinical trial will evaluate the efficacy and safety of a daily oral supplement containing Ashoka Bark and Shatavari in women with menopausal symptoms. The primary objectives are to assess changes in serum FSH and estradiol levels and improvements in menopausal symptoms measured by the MRS, GCS, and KMI. Secondary objectives include evaluating quality of life using the MENQOL questionnaire and changes in anxiety, cognitive function, and sleep disturbance using PROMIS measures. An exploratory objective will assess changes in the vaginal microbiome following treatment.\n\nValidated patient-reported outcome instruments, including the Menopausal Rating Scale (MRS), Greene Climacteric Scale (GCS), Kupperman Menopausal Index (KMI), Menopause-Specific Quality of Life Questionnaire (MENQOL), and Patient-Reported Outcomes Measurement Information System (PROMIS) measures, provide standardized methods for evaluating symptom severity and health-related quality of life in menopausal women. In addition, laboratory assessment of reproductive hormones, particularly FSH and estradiol, provides objective measures that complement clinical symptom assessment.\n\nThe study will be conducted at MusB Research (New Port Richey, Florida) and will randomize up to 50 participants to achieve 40 study completers (20 active treatment and 20 placebo). Participants will attend three study visits over 12 weeks: baseline (Week 0), midpoint (Week 6), and endpoint (Week 12). Assessments include informed consent, eligibility screening, blood collection for FSH and estradiol, validated symptom and quality-of-life questionnaires, safety monitoring, adherence assessment, and optional vaginal microbiome sampling. Participants will take one capsule daily containing either the active botanical formulation or placebo throughout the study.",[55,61],{"label":56,"type":57,"description":58,"interventionNames":59},"Ashoka Bark and Shatavari Intervention Arm","EXPERIMENTAL","Participants assigned to this arm will receive the active investigational supplement containing Ashoka Bark (Saraca asoca) and Shatavari (Asparagus racemosus). Participants will take one capsule daily (100 mg) orally before or during a meal for 12 weeks. The intervention is intended to evaluate the effect of the botanical formulation on menopausal symptoms, hormonal measures, quality of life, and exploratory microbiome outcomes. Participants will complete scheduled study assessments, symptom tracking, safety monitoring, and adherence evaluations throughout the intervention period.",[60],"Dietary Supplement: Ashoka Bark and Shatavari",{"label":62,"type":63,"description":64,"interventionNames":65},"Placebo Control Arm","PLACEBO_COMPARATOR","Participants assigned to this arm will receive a matched placebo capsule administered orally once daily before or during a meal for 12 weeks. The placebo will be identical in appearance to the active supplement to maintain blinding. Participants will undergo the same clinical assessments, symptom evaluations, safety monitoring, and adherence assessments as the intervention arm to allow comparison of outcomes between groups.",[66],"Other: Placebo",[68,80],{"type":69,"name":70,"description":71,"armGroupLabels":72,"otherNames":73},"DIETARY_SUPPLEMENT","Ashoka Bark and Shatavari","The intervention is an oral botanical dietary supplement containing Ashoka Bark (Saraca asoca) and Shatavari (Asparagus racemosus) intended for the management of menopausal symptoms. Participants will consume one capsule daily (100 mg) before or during a meal for 12 weeks. The formulation is being evaluated for its potential effects on menopausal symptom severity, hormone-related measures, quality of life, and related health outcomes in postmenopausal women. The intervention will be compared with a matched placebo under randomized, double-blind study conditions. Safety, adherence, and tolerability will be monitored throughout the study period.",[56],[74,75,76,77,78,79],"Ashoka Extract","Ashoka Bark Extract","Shatavari Extract","Saraca asoca Extract","Asparagus racemosus Extract","Beauty Within",{"type":81,"name":82,"description":83,"armGroupLabels":84,"otherNames":85},"OTHER","Placebo","Matched placebo capsule containing inactive ingredients, administered orally once daily before or during a meal for 12 weeks. The placebo is identical in appearance to the active Ashoka Bark and Shatavari supplement to maintain blinding of participants, investigators, and outcome assessors. The placebo contains no active botanical ingredients and is used as the comparator to evaluate the effects of the Ashoka Bark and Shatavari intervention on menopausal symptoms and related outcomes.",[62],[86],"Placebo Capsule",[88],{"facility":89,"status":90,"city":91,"state":92,"zip":93,"country":94,"countryCode":95,"cosmosGeoPoint":96,"geoPoint":101,"contacts":102},"MusB Research LLC","RECRUITING","New Port Richey","Florida","34653","United States","US",{"type":97,"coordinates":98},"Point",[99,100],-82.71927,28.24418,{"lat":100,"lon":99},[103],{"name":104,"role":105,"phone":106,"phoneExt":39,"email":107},"Prinicipal Investigator","CONTACT","8134190781","info@musbdiagnostics.com",{"type":109,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR",[111],{"name":112,"class":6},"MusB Research","100659162","satavari-and-ashoka-for-menopause-sam-study-100659162",false,"NCT07861295","Satavari and Ashoka for Menopause (SAM) Study","Shatavari & Ashoka for Menopause (SAM) Study","SAM","Inclusion Criteria:\n\n* Females aged 40-65 years.\n* Postmenopausal women in good overall health and fulfilling menopausal criteria set at the MRS score more than 5.\n* Subjects had experienced absence of regular menstrual cycle for at least 3 months.\n* Willingness to sign consent, follow protocols and regimen intake, as well as maintain normal physical activity and follow study procedures.\n\nExclusion Criteria:\n\n* Not on Hormone Replacement Therapy (HRT) or had discontinued HRT at least 12 months before admission to the study.\n* History of breast cancer,\n* BMI ≥ 40mg\u002Fkg².\n* Prior removal of both ovaries.\n* Pregnancy, breastfeeding, or plans for pregnancy.\n* History of breast or uterine cancer, including hyperplasia, endometrial carcinoma, or cervical neoplasia.\n* Unstable medical conditions or clinically diagnosed depression requiring treatment.\n* Self-reported drug or alcohol abuse.\n* Allergy or sensitivity to herbal ingredients.\n* Undiagnosed abnormal vaginal bleeding;\n* A bilateral hysterectomy;\n* History of chronic alcoholism,\n* Medication hypersensitivity, or allergy to dietary supplement ingredients;\n* Acute systemic infection or abnormal laboratory values.\n* No antibiotics use in past 30 days.\n* No regular probiotics use in past 30 days.","FEMALE","40 Years","65 Years",{"count":125,"type":126},50,"ESTIMATED","INTERVENTIONAL",[129],"NA","This 12-week randomized, placebo-controlled clinical trial will evaluate the efficacy and safety of a daily oral supplement containing Ashoka Bark and Shatavari in women experiencing menopausal symptoms. Up to 50 participants will be randomized to receive either the active supplement or placebo, with 40 participants expected to complete the study. Participants will attend visits at Weeks 0, 6, and 12, where hormone levels (FSH and estradiol), menopausal symptoms, quality of life, anxiety, cognitive function, and sleep will be assessed using validated measures. The study will also explore changes in the vaginal microbiome and monitor safety and adherence throughout the trial. The study will be conducted at MusB Research in New Port Richey, Florida.",[132],"Menopause",[132,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153],"Postmenopausal Women","Menopausal Symptoms","Ashoka Bark","Saraca asoca","Shatavari","Asparagus racemosus","Botanical Supplement","Herbal Supplement","Non-Hormonal Therapy","Dietary Supplement","Vasomotor Symptoms","Hot Flashes","Follicle-Stimulating Hormone","Estradiol","Menopausal Rating Scale","Greene Climacteric Scale","Kupperman Menopausal Index","Vaginal Microbiome","Women's Health","Randomized Placebo-Controlled Trial","2026-10-02",{"date":156,"type":157},"2026-10-06","ACTUAL",{"date":159,"type":157},"2025-10-01",{"date":161,"type":126},"2026-12-15",{"name":5,"class":6},1]